Carsten Utoft Niemann

90PUBLICATIONS
289CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Cancer geneticsSocial epidemiologyMedical mycology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (90)

|Oct 06, 2026
Telomere length in chronic lymphocytic leukemia treated with venetoclax-based regimen in GAIA/CLL13 and CLL2-GIVe trials.

|Oct 02, 2026
First-line ibrutinib-venetoclax in chronic lymphocytic leukemia: GLOW 67-month results and grade 3/4 adverse event-free progression-free survival.

|Sep 18, 2026
A functional prognostic model predicts progression-free survival in patients with relapsed chronic lymphocytic leukemia treated with ibrutinib + venetoclax.

|Aug 27, 2026
Refined Continuous Risk Index for Accurately Predicting Outcomes of Patients With Chronic Lymphocytic Leukemia After Limited-Duration Therapy.

|Aug 14, 2026
Treatment, Monitoring, and Management of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma: Evidence From a Multi-Country Needs Assessment.

|Jul 28, 2026
The Danish Lymphoid Cancer Research (DALY-CARE): Genetic Cohort Profile.

Pageof 15

Frequent Collaborators

30 joint publications

Christian Brieghel

16 joint publications

Arnon P Kater

12 joint publications

Moritz Fürstenau

11 joint publications

Caspar da Cunha-Bang